Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
U.S. federal corporate tax rate		35.00%	35.00%	35.00%
Additional income tax benefit due to tax rate change		$ 13,200
Tax Cuts and Jobs Act of 2017, Accounting Complete		false
Alternative minimum tax credit carry-forwards		$ 4,800,000	$ 4,800,000
Unused tax credit, period of refund		4 years
Limitation on use of carryforwards, cumulative change of control ownership interests, threshold percentage		50.00%
Limitation on use of carryforwards, cumulative change of control ownership interests, measurement period		3 years
Unused federal net operating loss carryforwards		$ 15,600,000
Unused federal net operating loss carryforwards expiring		5,100,000
Valuation allowance		98,609,000	63,225,000
Income tax expense		$ (28,526,000)	(6,665,000)	$ 8,311,000
Minimum
Recent Accounting Pronouncements
Expiration term for statute of limitations		3 years
Maximum
Recent Accounting Pronouncements
Expiration term for statute of limitations		5 years
Biotie Therapies Corp.
Income Tax [Line Items]
Foreign rate differential amount		$ 15,100,000
Biotie Therapies Corp. | U.S.
Income Tax [Line Items]
Reversed tax benefit of deferred tax liabilities related to indefinite lived intangibles		83,700,000
Biotie Therapies Corp. | Switzerland
Income Tax [Line Items]
Reversed tax benefit of deferred tax liabilities related to indefinite lived intangibles		5,400,000
Research and development and orphan drug
Income Tax [Line Items]
Tax credit carry-forwards		$ 34,500,000	39,000,000
Tax credit carry-forward, expiration beginning year		2031
Accounting Standards Update 2016-09
Income Tax [Line Items]
Adjustment to accumulated deficit		$ 12,100,000
Federal
Income Tax [Line Items]
Operating loss carryforwards		$ 144,400,000
Operating loss, expected expiration beginning year		2027
Federal | Biotie Therapies Corp.
Income Tax [Line Items]
Valuation allowance		$ 8,800,000
State
Income Tax [Line Items]
Operating loss carryforwards		$ 167,900,000	$ 170,900,000
Operating loss, expected expiration beginning year		2027
Outside U.S.
Income Tax [Line Items]
Operating loss carryforwards		$ 65,300,000
Outside U.S. | Biotie Therapies Corp.
Income Tax [Line Items]
Valuation allowance		28,500,000
Federal and State | Biotie Therapies Corp.
Income Tax [Line Items]
Valuation allowance		24,800,000
Biotie U.S and Foreign
Income Tax [Line Items]
Income tax expense		$ 0
Scenario, Forecast
Income Tax [Line Items]
U.S. federal corporate tax rate	21.00%